Cian Healthcare postal ballot seeks RPT nod, ₹100cr cap

What the company has put to shareholder vote

Cian Healthcare Limited has initiated a postal ballot to seek shareholder approval on a set of corporate actions that include material related party transactions with promoters. The notice also covers board-level appointments, including a Managing Director and a Woman Non-Executive Director. Alongside these items, the company is seeking approval to increase its borrowing and investment limits to ₹100 crore. The process is being conducted through remote e-voting as outlined in the postal ballot notice.

Postal ballot notice and regulatory context

The postal ballot notice has been dispatched under a disclosure described as being pursuant to Regulation 30 of the SEBI Listing Regulations. The company also referenced an “Outcome Of The Board Meeting-Approval Of Notice Of Postal Ballot” in the material provided. The disclosure timestamp in the supplied text is “30 May, 2026 | 06:28PM.”

In practical terms, a postal ballot allows companies to seek shareholder approval without convening a physical meeting, with voting conducted electronically. In this case, Cian Healthcare has specified remote e-voting dates and a record date to determine which shareholders are eligible to participate.

Key appointments proposed in the postal ballot

The postal ballot includes the appointment of Mr. Rajesh Jain as Managing Director. The term proposed is three years, running from March 16, 2026 to March 15, 2029. The notice also includes the appointment of Ms. Simmi Soni as a Woman Non-Executive Director.

Such appointments typically require shareholder approval under applicable company law and listing requirements, depending on the role, remuneration, and the company’s governance structure. The company’s communication, as provided, places these proposals alongside related party transaction approvals.

Material related party transactions with promoters

A central item in the postal ballot is approval for “material related party transactions with promoters.” The supplied text does not provide transaction-level details such as value, counterparties beyond “promoters,” or the specific nature of the transactions. Still, the inclusion of this resolution signals that the company is seeking shareholder consent for transactions that cross materiality thresholds under relevant regulations.

For listed companies, related party transactions are closely watched because they can affect minority shareholders. Shareholder voting is one mechanism intended to strengthen oversight and transparency.

Proposal to raise borrowing and investment limits to ₹100 crore

The notice also proposes increasing borrowing and investment limits to ₹100 crore. The provided material does not specify the current limits, the intended uses of higher borrowing capacity, or timelines. It also does not clarify whether the ₹100 crore covers borrowing, investment, or both collectively.

Even without those details, changes to borrowing and investment limits are typically positioned as enabling resolutions that provide flexibility to management, particularly for working capital, capex, or strategic initiatives.

Remote e-voting window and record date

Cian Healthcare has specified a record date of June 5, 2026, to determine shareholder eligibility. Remote e-voting opens on June 10, 2026 and closes on July 9, 2026. The company also stated that the announcement of results will be on or before July 13, 2026.

E-voting schedule

Scrutinizer appointment for the voting process

The Board has appointed Mrs. Divya Rani of M/s. Divya Rani & Associates as the Scrutinizer for the e-voting process. In postal ballots and e-voting, a scrutinizer’s role is to oversee the voting and validate the results process, providing a report to the company.

The supplied material also includes procedural references to NSDL e-voting steps and email IDs for coordination in the broader e-voting context, though the core schedule and scrutinizer information are the key voting-related facts stated for this postal ballot.

Company snapshot: operations and footprint

Cian Healthcare Limited is described as being headquartered in Pune, Maharashtra, and incorporated in 2003, with a founding date noted as January 7, 2003. The company engages in the development and manufacture of pharmaceuticals, cosmeceuticals, and nutraceutical products. The supplied text lists multiple therapeutic areas, including orthopedics, gynecology, pediatrics, cardiac, diabetic, dermatology, pain management, antibiotics, neuro, critical care, gastro-intestinal, CNS, vitamins and nutrient products.

The material also states that the firm’s business includes domestic products, contract manufacturing, exports, government tender, and innovative products. Export destinations listed include Afghanistan, Benin, Bhutan, Bolivia, Cambodia, Sri Lanka, and Myanmar.

Stock and financial datapoints mentioned in the supplied text

The provided material includes multiple market data snapshots for Cian Healthcare’s listed equity under the BSE ticker “CHCL.” One snapshot states a current price of 6.83 INR, up 1.98% over the past 24 hours. It also states market capitalization of 164.22 M INR, up 7.81% over the last week.

The same dataset states: “CHCL net income for the last half-year is −41.36 M INR,” compared with “−182.50 M INR” in the previous report, described as a 77.34% change. Separately, another snapshot lists “Market Cap ₹ 10.2 Cr.” and “Current Price ₹ 4.07,” along with “Book Value ₹ 15.8,” “ROCE 5.22%,” “ROE 0.43%,” and “Face Value ₹ 10.0.” It also states: promoter holding is 27.1%, promoters have pledged 34.5% of their holding, and promoter holding has decreased over the last 3 years by −39.2%.

Key facts cited in the supplied material

Why these resolutions matter for investors

A postal ballot that bundles related party transaction approvals and top management appointments is typically a governance-sensitive event. For minority shareholders, voting is the main formal channel to accept or reject proposals involving promoters, particularly when transactions are described as “material.”

The proposal to raise borrowing and investment limits to ₹100 crore is also a meaningful control item, because it can expand financial flexibility. Investors often evaluate such enabling resolutions alongside disclosures on business performance and capital allocation. In this case, the supplied material also references net income figures for the last half-year and a prior report, offering additional context around recent performance.

Conclusion

Cian Healthcare’s postal ballot process puts multiple governance and capital-related decisions to shareholder vote, including material related party transactions with promoters, director appointments, and a ₹100 crore borrowing and investment limit proposal. Remote e-voting is open from June 10, 2026 to July 9, 2026, with June 5, 2026 set as the record date. The company has indicated results will be announced on or before July 13, 2026, following scrutiny overseen by the appointed scrutinizer.